{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:18:58Z","timestamp":1780046338143,"version":"3.53.1"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100031585","name":"Takeda Development Center Americas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effectiveness\/safety of three proteasome inhibitors (PIs), plus lenalidomide\u2010dexamethasone (Rd) triplet regimens, for the treatment of relapsed\/refractory multiple myeloma (RRMM) in a real\u2010world setting, using data from the observational INSIGHT\u2010MM study (NCT02761187).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with RRMM who received ixazomib, carfilzomib, or bortezomib plus Rd (IRd, KRd, or VRd, respectively) in the second or later line of therapy (LoT) were included. Patient characteristics, response to therapy (Kaplan\u2013Meier analysis), and safety were reported descriptively. Multivariable Cox proportional hazards models were used to assess comparative effectiveness between regimens, whilst adjusting for cohort imbalances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 356 LoTs (IRd\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009181; KRd\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200996; VRd\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200979) from 348 patients were included. There was heterogeneity in patient characteristics between cohorts. Median real\u2010world progression\u2010free survival (rwPFS) for IRd, KRd, and VRd was 14.5, 13.2, and 9.1\u2009months, respectively. After adjustment for baseline covariates, no significant differences in rwPFS were observed between regimens. All three regimens demonstrated a manageable safety profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IRd, KRd, and VRd demonstrated comparable effectiveness and safety for the treatment of RRMM in a real\u2010world setting, highlighting the need for a holistic evaluation of individual patients' needs and circumstances when selecting an appropriate PI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Registration<\/jats:title>\n                    <jats:p>\n                      Clinical trial registration for the INSIGHT\u2010MM study: NCT02761187;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02761187\">https:\/\/clinicaltrials.gov\/study\/NCT02761187<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70079","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:01:24Z","timestamp":1768388484000},"page":"458-470","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness and Safety of\n                    <scp>PI\u2010Rd<\/scp>\n                    Triplets in Relapsed\/Refractory Multiple Myeloma:\n                    <scp>INSIGHT\u2010MM<\/scp>\n                    Data Analysis"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noemi","family":"Puig","sequence":"first","affiliation":[{"name":"University Hospital of Salamanca  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"CHU Poitiers  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[{"name":"NYU Langone  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[{"name":"Department of Haematooncology University Hospital Ostrava  Ostrava Czech Republic"},{"name":"Department of Haematooncology, Faculty of Medicine University of Ostrava  Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[{"name":"Clinica Sao Germano  Sao Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Tempus AI  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Vela","family":"Ojeda","sequence":"additional","affiliation":[{"name":"Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[{"name":"Universitaetsklinikum Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Tennessee Oncology  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-3473","authenticated-orcid":false,"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[{"name":"University of Patras Medical School &amp; Olympion Hospital  Patras Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Nascimento\u2010Ferreira","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG  Opfikon Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arthur","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA)  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Mokr\u00e1","sequence":"additional","affiliation":[{"name":"Institut biostatistiky a anal\u00fdz, s.r.o.  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Ren","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA)  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA)  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results (SEER) Program \u201cCancer Stat Facts: Myeloma \u201d (2024).","DOI":"10.1093\/jncimonographs\/lgae033"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00912-9"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1225"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0272-0"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0013"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.12.003"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03981-z"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.14735\/amko20172S43"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0250-z"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2350.2350"},{"key":"e_1_2_12_16_1","unstructured":"Multiple Myeloma Research Foundation \u201cMMRF CoMMpass Study \u201d (2018)."},{"key":"e_1_2_12_17_1","article-title":"Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect\u00ae MM Registry: Observations Over Time in Cohort 1 (2009\u20132011) and Cohort 2 (2012\u20132016)","volume":"130","author":"Narang M.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.018"},{"key":"e_1_2_12_19_1","article-title":"Healthcare Resource Utilization and Costs Associated With Different Treatment Modalities of Relapsed\/Refractory Multiple Myeloma Patients in the US: Findings From Preamble","volume":"130","author":"Kuter D. J.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.229"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-018-0953-4"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0785-z"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000045"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000683"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2024.101078"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1729734"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04534-8"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00972"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194592"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.23031"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:47:53Z","timestamp":1780044473000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/ejh.70079"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70079","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"2025-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}